IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In Re Application of: EISENBACH-SCHWARTZ et al Art Unit: 1644 JUN 19 2000 Examiner: S. Turner Application No.: 09/218,277 Filed: December 22, 1998 Washington, D.C. TECH CENTER 1600/2900 Atty.'s Docket: EIS-SCHWARTZ=1A T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND THEIR Date: June 16, 2000 RECEIVED JUN 1 6 2000 THE COMMISSIONER OF PATENTS AND TRADEMARKS JUN 20 2000 Washington, D.C. 20231 TECH CENTER 1600/2900 Transmitted herewith is a [] Amendment [XX] Response to Notice to Compt Sequence Listing Requirements and disk in the above-identified application. Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed. No additional fee is required. The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)		
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS		
TOTAL	*	MINUS	** 20	0		
INDEP.	*	MINUS	*** 3	0		
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						

_	SMALL ENTITY				
		RATE	ADDITIONAL FEE		
	х	9	\$		
	х	39	\$		
	+	130	\$		
ADDITIONAL FEE TOTAL			\$		

Other Than Small Entity

OTHER THAN SMALL ENTITY RATE **ADDITIONAL** 18 78 \$ \$ 260 TOTAL

If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

Conditional Petition for Extension of Time

Small Entity

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

	ornan Ettity	
	Response Filed Within	Response Filed Within
	[] First - \$ 55.00	[] First - \$ 110.00
	[] Second - \$ 190.00	[] Second - \$ 380.00
	[] Third - \$ 435.00	[] Third - \$ 870.00
	[] Fourth - \$ 680.00	[] Fourth - \$ 1360.00
	Month After Time Period Set	Month After Time Period Set
[]	[] Less fees (\$) already paid for month(s) extends the second of the second	•
[]	Please charge my American Express Account, Form PTO-2038	8 attached, in the amount of \$
[]	A check in the amount of \$ is attached (check no.).
[XX]	The Commissioner is hereby authorized and requested to char overpayment to Deposit Account No. 02-4035. This authorizati	, ,

nection with this application or credit any ssociated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

Allen C. Yun

Registration No. 37,971

Facsimile: Telephone:

(202) 737-3528 (202) 628-5197

OR

OR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 1 6 2000

In re Application of:

EISENBACH-SCHWARTZ et

Appln. No.: 09/218,277

Filed: December 22, 199

For: T-CELLS, NERVOUS SYSTEM-

SPECIFIC ANTIGENS AND

THEIR USES

Art Unit: 1644

Examiner: S. Turner

Washington, D.C.

June 16, 2000

Atty.Docket:

EIS-SCHWARTZ=1A

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS

Honorable Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice to Comply, dated May 26, 2000, please amend the present application as follows:

IN THE SPECIFICATION

Page 10, line 25, after "SEQ ID NO:" insert --1--;
line 28, after "SEQ ID NO:" insert --2--;
line 32, after "SEQ ID" replace "NO:" with

__Nos:3-8__.

Page 11, line 5, after "SEQ ID NO:" insert —9—;
line 10, after "SEQ ID NO:" insert —10—;
line 14, after "SEQ ID NO:" insert —11—;
line 18, after "SEQ ID NO:" insert —12—;
line 22, after "SEQ ID NO:" insert —13—;
line 24, after "SEQ ID NO:" insert —14—.

Page 18, line 27, after "SEQ ID NO:" insert —12—;
line 28, after "SEQ ID NO:" insert —13—;
line 29, after "SEQ ID NO:" insert —13—;